Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
Npj Precision Oncology
Mansfield, A S AS; Wei, Z Z; Mehra, R R; Shaw, A T AT; Lieu, C H CH; Forde, P M PM; Drilon, A E AE; Mitchell, E P EP; Wright, J J JJ; Takebe, N N; Sharon, E E; Hovelson, D D; Tomlins, S S; Zeng, J J; Poorman, K K; Malik, N N; Gray, R J RJ; Li, S S; McShane, L M LM; Rubinstein, L V LV; Patton, D D; Williams, P M PM; Hamilton, S R SR; Conley, B A BA; Arteaga, C L CL; Harris, L N LN; O'Dwyer, P J PJ; Chen, A P AP; Flaherty, K T KT